The expansion of Arch Oncology’s leadership comes after a raise of $105 million in Series C financing in April to advance clinical efforts on its lead drug candidate. In February, the 30-person startup said it inked a clinical trial collaboration and supply agreement with New Jersey-based Merck to assess AO-176 in combination with Merck’s cancer drug KEYTRUDA for patients with select solid tumors…
